ETANA AND BOGOR CITY GOVERNMENT STRENGTHEN CHILD HEALTH THORIUGH VACCINE

Bogor, April 30, 2025 – In commemoration of World Immunization Week 2025, PT Etana Biotechnologies Indonesia (Etana), in collaboration with the Bogor City Government, conducted a vaccination program for children. A total of 2.081 doses of Hepatitis A and PCV13 vaccines were administered during a series of events held at Bogor City Hall, Boxies Mall, and several schools across the city.

Read More
Lusy Andriani
ETANA SUPPORTS INNOVATIVE KIDNEY DISEASE TREATMENT IN INDONESIA

Jakarta, March 14, 2025 – In commemoration of World Kidney Day, Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting innovation in kidney disease treatment in Indonesia. As a biotechnology company, Etana actively contributes to providing high-quality and affordable medicines for patients, especially those suffering from kidney disease. 

Read More
Lusy Andriani
COMMEMORATING WORLD CANCER DAY, ETANA REAFFIRMS COMMITMENT TO DEVELOPING CANCER TREATMENTS IN INDONESIA

Jakarta, 5 February 2025 – In commemoration of World Cancer Day, Etana Biotechnologies Indonesia (Etana) reaffirmed its commitment to providing high-quality and affordable cancer treatment solutions. As a local biopharmaceutical company, Etana continues to innovate in developing and producing medicines that are accessible to cancer patients across Indonesia.

Read More
Lusy Andriani
ETANA LAUNCHES INNOVATIVE CANCER THERAPIES IN INDONESIA THROUGH COLLABORATION WITH BEIGENE

Jakarta, December 10, 2024 – PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has obtained marketing authorization for two innovative cancer therapies, Tislelizumab (ETAPIDI®) and Zanubrutinib (BRUKINSA®). Developed by BeiGene, which plans to change its name to BeOne Medicines, a global oncology leader committed to making cutting-edge and accessible treatments available worldwide, these therapies are set to transform cancer care in Indonesia by combining global advancements with local accessibility.

Read More
Lusy Andriani